Share your experiences, tips, and questions in the comments below
Currently available FDA-approved GLP-1 RAs include several monotherapy agents and one combination multi-agonist, the dual GLP-1/GIP agonist tirzepatide (Zheng et al., 2024)
Clinical studies (in both obesity and type 2 diabetes) consistently show that GLP-1 RA treatment leads to less hunger, increased satiety, and spontaneous decreases in daily caloric consumption (Zheng et al., 2024)
However, when we get more than the minimum amount of each nutrient we need, we experience sensory-specific satiety and our cravings subside
Low-Glycemic Carbohydrates Examples: Sweet potatoes, quinoa, whole grains, dairy, nuts, oats, legumes, non-starchy vegetables
Drugs 82, 12131220